Teniposide Suppliers & Bulk Manufacturers

Available Forms: Injection (IV)

Available Strengths: 50 mg/5 mL (10 mg/mL vial)

Reference Brands: Vumon® (EU & US)

Category: Oncology Cancer Care

Teniposide is a topoisomerase II inhibitor used in oncology, primarily for treating acute lymphoblastic leukemia (ALL) in pediatric patients. Marketed under the brand name Vumon®, it is available in 50 mg/5 mL (10 mg/mL) IV vials in both the US and EU. Teniposide is a critical component in combination chemotherapy protocols and is supplied under GMP-compliant manufacturing. Ideal for pharma B2B partners, Teniposide supports trusted oncology supply chains across regulated markets. Teniposide is available in Injection (IV) and strengths such as 50 mg/5 mL (10 mg/mL vial). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Teniposide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Teniposide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Teniposide Injection is a potent chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric patients with relapsed or refractory disease. Classified as a topoisomerase II inhibitor, Teniposide disrupts DNA replication and cell division, making it effective in oncology protocols. It is commercially available in the US and EU under the brand name Vumon®, typically in 50 mg/5 mL (10 mg/mL) injectable vials. Teniposide is manufactured under strict GMP standards, making it ideal for B2B pharmaceutical distributors, hospital tenders, and global supply chains seeking reliable oncology solutions in regulated markets.